JP2008517871A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517871A5
JP2008517871A5 JP2007515393A JP2007515393A JP2008517871A5 JP 2008517871 A5 JP2008517871 A5 JP 2008517871A5 JP 2007515393 A JP2007515393 A JP 2007515393A JP 2007515393 A JP2007515393 A JP 2007515393A JP 2008517871 A5 JP2008517871 A5 JP 2008517871A5
Authority
JP
Japan
Prior art keywords
composition
balsalazide
administered
cancer
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515393A
Other languages
English (en)
Japanese (ja)
Other versions
JP5009152B2 (ja
JP2008517871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018757 external-priority patent/WO2005117851A1/en
Publication of JP2008517871A publication Critical patent/JP2008517871A/ja
Publication of JP2008517871A5 publication Critical patent/JP2008517871A5/ja
Application granted granted Critical
Publication of JP5009152B2 publication Critical patent/JP5009152B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515393A 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復 Expired - Fee Related JP5009152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60895104P 2004-05-28 2004-05-28
US60/608,951 2004-10-26
PCT/US2005/018757 WO2005117851A1 (en) 2004-05-28 2005-05-27 Prevention, treatment, and amelioration of radiation induced enteritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011233631A Division JP2012021031A (ja) 2004-10-26 2011-10-25 放射線誘発性腸炎の予防、処置、および回復

Publications (3)

Publication Number Publication Date
JP2008517871A JP2008517871A (ja) 2008-05-29
JP2008517871A5 true JP2008517871A5 (enExample) 2008-07-10
JP5009152B2 JP5009152B2 (ja) 2012-08-22

Family

ID=40096437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515393A Expired - Fee Related JP5009152B2 (ja) 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復

Country Status (4)

Country Link
US (3) US20080306029A1 (enExample)
JP (1) JP5009152B2 (enExample)
KR (1) KR20130028807A (enExample)
DE (1) DE602005022175D1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита
CA3259788A1 (en) * 2022-06-22 2023-12-28 Marjan BOERMA METHOD FOR ATTENUATING INJURY BY RADIATION USING GERANYL TRANSFERASE INHIBITORS
CN115252685A (zh) * 2022-06-24 2022-11-01 内蒙古民族大学附属医院 一种蒙药巴特日-7在预防和治疗放射性肠道损伤中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
EP0439453B1 (en) * 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
DE69839261T2 (de) * 1997-04-01 2009-03-26 Borody, Thomas Julius, Five Dock Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20030078205A1 (en) * 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6517871B1 (en) * 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
EP1313699B1 (en) * 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
JPWO2004082715A1 (ja) * 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate

Similar Documents

Publication Publication Date Title
Di Donato et al. Vaginal cancer
JP2020143134A5 (enExample)
JP2009545602A5 (ja) 放射線直腸ｓ状結腸炎を処置するための組成物および方法
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
JP2017039771A5 (enExample)
NZ621449A (en) Treatment with anti-vegf antibodies
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MX2013010770A (es) Tratamiento de tumores solidos.
CN102264347A (zh) 灌肠制剂及其应用
JP2021105005A5 (enExample)
Le et al. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin
JP2008517871A5 (enExample)
WO2005087206A3 (en) Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
WO2019017497A1 (en) USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
ATE499378T1 (de) Anthracyclinderivate
CA2556373A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
Pawara et al. Recent progress in polymeric nano-structures in photo-chemotherapy and hyperthermia therapy in triple-negative breast cancer treatment: A review
White et al. Complete resolution of urinary bladder condyloma acuminatum following definitive chemoradiotherapy for anal cancer
Makar et al. Vulvar And Vaginal Cancers In Flanders. Data From The Flemish Society Of Gynaecologic Oncology
HARIMA et al. Preliminary study of the combination of radiation therapy, chemotherapy, and hyperthermia in Stage IIIB cervical carcinoma
Xiao-yan et al. Research Progress on Chemotherapy of Endometrial Carcinoma
Suprasert et al. Efficacy of Cisplatin in Early Stage Cervical Cancer With Long Waiting Period for Surgery
Padovani et al. Chemotherapy in Rectal Cancer